Cognito Therapeutics vs BioNTech

Side-by-side comparison of AI visibility scores, market position, and capabilities

BioNTech leads in AI visibility (88 vs 41)
Cognito Therapeutics logo

Cognito Therapeutics

EmergingMedTech

Neurostimulation

Raised $105M oversubscribed Series C (Mar 2026) led by Morningside Ventures. HOPE pivotal trial fully enrolled. Non-pharmacological Alzheimer's device targeting FDA clearance.

AI VisibilityBeta
Overall Score
C41
Category Rank
#1 of 1
AI Consensus
39%
Trend
up
Per Platform
ChatGPT
52
Perplexity
32
Gemini
36

About

Cognito Therapeutics is developing a non-pharmacological treatment for Alzheimer's disease using coordinated gamma-frequency light and sound stimulation — a technology called sensory entrainment that modulates neural oscillations implicated in the disease. The company raised an oversubscribed $105 million Series C in March 2026 led by Morningside Ventures, with its pivotal HOPE clinical trial fully enrolled and topline data expected in late 2026.

Full profile
BioNTech logo

BioNTech

LeaderLife Sciences & BioTech

mRNA Therapeutics

German mRNA pioneer co-developed COVID-19 vaccine with Pfizer; 20+ clinical programs in oncology and infectious disease; pivoting to mRNA cancer immunotherapies with BNT111 melanoma vaccine evaluated in combination with Regeneron's cemiplimab as key pipeline asset.

AI VisibilityBeta
Overall Score
A88
Category Rank
#1 of 1
AI Consensus
52%
Trend
up
Per Platform
ChatGPT
80
Perplexity
86
Gemini
82

About

BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneered individualized neoantigen-specific immunotherapy and mRNA-based therapeutic approaches before co-developing the world's first authorized mRNA vaccine with Pfizer during the COVID-19 pandemic.\n\nBioNTech's pipeline spans over 20 clinical programs in oncology, infectious disease, and autoimmune conditions. Key assets include BNT111, an mRNA cancer vaccine for melanoma evaluated in combination with Regeneron's cemiplimab, as well as a suite of CAR-T, bispecific antibody, and mRNA-encoded cytokine programs. The company manufactures mRNA therapies at scale through its BioNTainer modular facilities deployable to emerging markets.\n\nBioNTech generated approximately €2.4 billion in revenue in 2024 and holds a robust cash position exceeding €17 billion, enabling sustained R&D investment. The company is recognized as one of the most pivotal biotech success stories of the 21st century, combining deep immunology science with scalable mRNA manufacturing to pursue a world where cancer is a manageable disease.

Full profile

AI Visibility Head-to-Head

41
Overall Score
88
#1
Category Rank
#1
39
AI Consensus
52
up
Trend
up
52
ChatGPT
80
32
Perplexity
86
36
Gemini
82
33
Claude
99
52
Grok
80

Key Details

Category
Neurostimulation
mRNA Therapeutics
Tier
Emerging
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Cognito Therapeutics
Neurostimulation
Only BioNTech
mRNA Therapeutics

Integrations

Only BioNTech

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.